News and Updates
Keep up to date with the latest news at Parkinson’s Care and Support UK as well as developments from the world of Parkinson’s.
Registration is now open for The Jubilee River Swim 2020!
We are excited to announce that Parkinson’s Care and Support UK, have places to offer for The Jubilee River Swim 2020! The Jubilee River Swim has become one of the countries favourite swims.
The man made flood relief channel between Boulters Lock nr Maidenhead and Pococks Lane in Eton is free from craft and is a convenient length at 10km! There are three weirs along the rivers length that break up the swim nicely, and you’ll find feed stations here.
Please note – this is a solo swim event, there is no relay option.
This is a great swim experience where swimmers take on the challenge of this beautiful 10km river and entrants can be as young as 13 years old!
This is one not to miss. Entries closed many months before the day so get your entry in early!
About this event
Date: Sunday June 07, 2020
Venue: Royal Windsor Racecourse
Maidenhead Road Windsor, United Kingdom SL4 5JJ
Registration Fee: £85
Minimum Sponsorship: £400
Register your interest now!
More Evidence that Parkinson’s Originates in the Gut -August 2019
Researchers at Johns Hopkins Medicine conducted studies in mice to investigate whether the toxic misfolded alpha-synuclein protein, which is a hallmark of Parkinson’s, could travel along the vagus nerve, which runs like an electrical cable between the stomach and small intestine into the base of the brain.
This study was prompted by previous research by German neuroanatomist, Heiko Braak, that showed people with Parkinson’s had a build-up of the misfolded alpha-synuclein in parts of the central nervous system that control the gut. Evidence from this latest study showed that alpha-synuclein began building where the vagus nerve connected to the gut and continued to spread through all parts of the brain.
It also demonstrated that blocking the transmission route could be key to preventing the physical and cognitive manifestations of Parkinson’s.
“These findings provide further proof of the gut’s role in Parkinson’s disease, and gives us a model to study the disease’s progression from the start… This is an exciting discovery for the field and presents a target for early intervention in the disease,” Says Professor Ted Dawson, M.D. Ph.D, Director of the Johns Hopkins Institute for Cell Engineering, Professor of Neurology at the Johns Hopkins University School of Medicine and a member of CPT’s Linked Clinical Trials committee
The Importance of Microglia in the Parkinson’s brain- August 2019
Microglia are a crucial population of helper cells whose primary function is to act as resident immune cells within the brain. They function like a ‘special force’, linked to the body’s immune system. They deal with injury/infection in the brain and communicate with the immune system about how best to cope with a developing condition. When microglia sense trouble in the brain, they will start to evaluate whether the affected cells need to be killed off or nurtured back to health.
Researchers at the Van Andel Institute in Grand Rapids (Michigan, USA) recently published a report demonstrating that microglia are significantly involved in the cell-to-cell transfer of the protein alpha-synuclein. This Parkinson’s-associated protein is believed to pass from one cell to another, and during this passage the alpha-synuclein begin to clump or aggregate within the cells. This process is how researchers believe the progressive nature of Parkinson’s is manifesting itself within the brain.
The Van Andel Institute researchers reported that the removal of microglia from the brain resulted in greater aggregation of alpha-synuclein, as did the hyperactivation of the microglia when a chemical used to induce inflammation was introduced. Their results suggest that under normal resting or ‘non-inflammatory’ conditions, microglia play an important role in modulating the transfer of alpha-synuclein in models of Parkinson’s.
Regulating microglia and neuroinflammation could represent a future avenue for limiting the progression of Parkinson’s – by reducing the spread of alpha-synuclein in the brain.